• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种前药激活酶 hVACVase 的特异性:离去基团效应。

Specificity of a prodrug-activating enzyme hVACVase: the leaving group effect.

机构信息

Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, 428 Church Street, Ann Arbor, Michigan 48109-1065, United States.

出版信息

Mol Pharm. 2010 Dec 6;7(6):2362-8. doi: 10.1021/mp100300k. Epub 2010 Nov 11.

DOI:10.1021/mp100300k
PMID:21028903
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2997884/
Abstract

Human valacyclovirase (hVACVase) is a prodrug-activating enzyme for amino acid prodrugs including the antiviral drugs valacyclovir and valganciclovir. In hVACVase-catalyzed reactions, the leaving group of the substrate corresponds to the drug moiety of the prodrug, making the leaving group effect essential for the rational design of new prodrugs targeting hVACVase activation. In this study, a series of valine esters, phenylalanine esters, and a valine amide were characterized for the effect of the leaving group on the efficiency of hVACVase-mediated prodrug activation. Except for phenylalanine methyl and ethyl esters, all of the ester substrates exhibited a relatively high specificity constant (k(cat)/K(m)), ranging from 850 to 9490 mM(-1)·s(-1). The valine amide Val-3-APG exhibited significantly higher K(m) and lower k(cat) values compared to the corresponding ester Val-3-HPG, indicating poor specificity for hVACVase. In conclusion, the substrate leaving group has been shown to affect both binding and specific activity of hVACVase-catalyzed activation. It is proposed that hVACVase is an ideal target for α-amino acid ester prodrugs with relatively labile leaving groups while it is relatively inactivate toward amide prodrugs.

摘要

人丙氧鸟苷酶(hVACVase)是一种前体药物激活酶,可激活包括抗病毒药物伐昔洛韦和缬更昔洛韦在内的氨基酸前体药物。在 hVACVase 催化的反应中,底物的离去基团对应于前体药物的药物部分,因此对于针对 hVACVase 激活的新前体药物的合理设计,离去基团效应至关重要。在这项研究中,我们对一系列缬氨酸酯、苯丙氨酸酯和缬氨酸酰胺进行了表征,以研究离去基团对 hVACVase 介导的前体药物激活效率的影响。除了苯丙氨酸甲酯和乙酯外,所有的酯类底物都表现出相对较高的特异性常数(k(cat)/K(m)),范围为 850 到 9490mM(-1)·s(-1)。与相应的酯 Val-3-HPG 相比,缬氨酸酰胺 Val-3-APG 表现出明显更高的 K(m)和更低的 k(cat)值,表明其对 hVACVase 的特异性较差。总之,研究表明,底物的离去基团既影响 hVACVase 催化的激活的结合,又影响其特异性活性。可以提出 hVACVase 是相对不稳定离去基团的α-氨基酸酯前体药物的理想靶标,而对于酰胺前体药物,则相对不活跃。

相似文献

1
Specificity of a prodrug-activating enzyme hVACVase: the leaving group effect.一种前药激活酶 hVACVase 的特异性:离去基团效应。
Mol Pharm. 2010 Dec 6;7(6):2362-8. doi: 10.1021/mp100300k. Epub 2010 Nov 11.
2
A novel nucleoside prodrug-activating enzyme: substrate specificity of biphenyl hydrolase-like protein.一种新型核苷前药激活酶:类联苯水解酶蛋白的底物特异性
Mol Pharm. 2004 Mar-Apr;1(2):117-27. doi: 10.1021/mp0499757.
3
Molecular basis of prodrug activation by human valacyclovirase, an alpha-amino acid ester hydrolase.人伐昔洛韦酶(一种α-氨基酸酯水解酶)激活前药的分子基础。
J Biol Chem. 2008 Apr 4;283(14):9318-27. doi: 10.1074/jbc.M709530200. Epub 2008 Feb 5.
4
Enhancing the intestinal absorption of molecules containing the polar guanidino functionality: a double-targeted prodrug approach.增强含有极性胍基官能团的分子的肠道吸收:一种双靶向前药方法。
J Med Chem. 2010 Jan 28;53(2):624-32. doi: 10.1021/jm9011559.
5
Structure and specificity of a human valacyclovir activating enzyme: a homology model of BPHL.人伐昔洛韦激活酶的结构与特异性:BPHL的同源模型
Mol Pharm. 2004 Nov-Dec;1(6):434-46. doi: 10.1021/mp049959+.
6
Chemical and enzymatic stability of amino acid prodrugs containing methoxy, ethoxy and propylene glycol linkers.含有甲氧基、乙氧基和丙二醇连接基的氨基酸前药的化学和酶稳定性
Mol Pharm. 2009 Sep-Oct;6(5):1604-11. doi: 10.1021/mp900084v.
7
Acyloxymethyl as a drug protecting group: Part 4. The hydrolysis of tertiary amidomethyl ester prodrugs of carboxylic acid agents.酰氧基甲基作为药物保护基:第4部分。羧酸类药物的叔胺甲基酯前药的水解
Pharm Res. 1997 Nov;14(11):1634-9. doi: 10.1023/a:1012146905833.
8
Pharmacokinetic studies of naproxen amides of some amino acid esters with promising colorectal cancer chemopreventive activity.具有潜在结直肠癌化学预防活性的一些氨基酸酯的萘普生酰胺的药代动力学研究。
Bioorg Chem. 2018 Feb;76:370-379. doi: 10.1016/j.bioorg.2017.12.006. Epub 2017 Dec 2.
9
Enzymatic activation of double-targeted 5'-O-L-valyl-decitabine prodrug by biphenyl hydrolase-like protein and its molecular design basis.联苯水解酶样蛋白对双靶点5'-O-L-缬氨酰地西他滨前药的酶促激活作用及其分子设计基础。
Drug Deliv Transl Res. 2017 Apr;7(2):304-311. doi: 10.1007/s13346-016-0356-1.
10
Substrate-Competitive Activity-Based Profiling of Ester Prodrug Activating Enzymes.基于底物竞争活性的酯前药激活酶分析
Mol Pharm. 2015 Sep 8;12(9):3399-407. doi: 10.1021/acs.molpharmaceut.5b00414. Epub 2015 Aug 17.

引用本文的文献

1
Prodrug Therapies for Infectious and Neurodegenerative Diseases.用于感染性疾病和神经退行性疾病的前药疗法。
Pharmaceutics. 2022 Feb 26;14(3):518. doi: 10.3390/pharmaceutics14030518.
2
Prodrugs for Improved Drug Delivery: Lessons Learned from Recently Developed and Marketed Products.用于改善药物递送的前药:从近期研发和上市产品中汲取的经验教训。
Pharmaceutics. 2020 Oct 29;12(11):1031. doi: 10.3390/pharmaceutics12111031.
3
Computational Simulations to Guide Enzyme-Mediated Prodrug Activation.计算模拟指导酶介导的前药激活。
Int J Mol Sci. 2020 May 20;21(10):3621. doi: 10.3390/ijms21103621.
4
Computational modeling and in-vitro/in-silico correlation of phospholipid-based prodrugs for targeted drug delivery in inflammatory bowel disease.用于炎症性肠病靶向给药的基于磷脂的前药的计算建模与体外/计算机模拟相关性研究
J Comput Aided Mol Des. 2017 Nov;31(11):1021-1028. doi: 10.1007/s10822-017-0079-5. Epub 2017 Nov 3.
5
Enzymatic activation of double-targeted 5'-O-L-valyl-decitabine prodrug by biphenyl hydrolase-like protein and its molecular design basis.联苯水解酶样蛋白对双靶点5'-O-L-缬氨酰地西他滨前药的酶促激活作用及其分子设计基础。
Drug Deliv Transl Res. 2017 Apr;7(2):304-311. doi: 10.1007/s13346-016-0356-1.
6
Modern prodrug design for targeted oral drug delivery.用于靶向口服给药的现代前药设计。
Molecules. 2014 Oct 14;19(10):16489-505. doi: 10.3390/molecules191016489.
7
Synthesis and characterization of valyloxy methoxy luciferin for the detection of valacyclovirase and peptide transporter.用于伐昔洛韦酶和肽转运体检测的缬氨酰氧基甲氧基荧光素的合成与表征
Bioorg Med Chem Lett. 2014 Oct 15;24(20):4781-4783. doi: 10.1016/j.bmcl.2014.09.011. Epub 2014 Sep 16.

本文引用的文献

1
Enhancing the intestinal absorption of molecules containing the polar guanidino functionality: a double-targeted prodrug approach.增强含有极性胍基官能团的分子的肠道吸收:一种双靶向前药方法。
J Med Chem. 2010 Jan 28;53(2):624-32. doi: 10.1021/jm9011559.
2
Molecular basis of prodrug activation by human valacyclovirase, an alpha-amino acid ester hydrolase.人伐昔洛韦酶(一种α-氨基酸酯水解酶)激活前药的分子基础。
J Biol Chem. 2008 Apr 4;283(14):9318-27. doi: 10.1074/jbc.M709530200. Epub 2008 Feb 5.
3
Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting.用于改善口服吸收和组织靶向性的核苷类似物前药。
J Pharm Sci. 2008 Mar;97(3):1109-34. doi: 10.1002/jps.21047.
4
Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel.抗流感前体药物奥司他韦由羧酸酯酶人羧酸酯酶1激活,且该激活作用被抗血小板药物氯吡格雷抑制。
J Pharmacol Exp Ther. 2006 Dec;319(3):1477-84. doi: 10.1124/jpet.106.111807. Epub 2006 Sep 11.
5
Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy.抗病毒前体药物——抗病毒化疗成功前体药物策略的发展
Br J Pharmacol. 2006 Jan;147(1):1-11. doi: 10.1038/sj.bjp.0706446.
6
Nucleoside ester prodrug substrate specificity of liver carboxylesterase.肝脏羧酸酯酶的核苷酯前药底物特异性
J Pharmacol Exp Ther. 2006 Feb;316(2):572-80. doi: 10.1124/jpet.105.092726. Epub 2005 Oct 13.
7
A novel nucleoside prodrug-activating enzyme: substrate specificity of biphenyl hydrolase-like protein.一种新型核苷前药激活酶:类联苯水解酶蛋白的底物特异性
Mol Pharm. 2004 Mar-Apr;1(2):117-27. doi: 10.1021/mp0499757.
8
Lessons learned from marketed and investigational prodrugs.从已上市和正在研究的前药中吸取的经验教训。
J Med Chem. 2004 May 6;47(10):2393-404. doi: 10.1021/jm0303812.
9
Enzyme-catalyzed activation of anticancer prodrugs.酶催化的抗癌前药激活
Pharmacol Rev. 2004 Mar;56(1):53-102. doi: 10.1124/pr.56.1.3.
10
MECHANISM OF ACTION OF PROTEOLYTIC ENZYMES.蛋白水解酶的作用机制
Annu Rev Biochem. 1965;34:49-76. doi: 10.1146/annurev.bi.34.070165.000405.